Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$68.98 USD
-2.71 (-3.78%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HALO 68.98 -2.71(-3.78%)
Will HALO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Other News for HALO
Is HALO signaling selling opportunity? Fell Below 50 Day Moving Average shows up after sinking 3.78%
HALO forms 50 Day Moving Average Support on October 2
Halozyme Announces Merger Agreement with Elektrofi
Stochastic Buy Signal appears for HALO after 2.18% move
HC Wainwright & Co. Raises Price Target for Halozyme Therapeutics (HALO) | HALO Stock News